BIO NYSE
Credit Risk of going bust: lower than 70% of companies Debt: 10.6% of company value Bonds: $41.6M held by 57 funds, 79 bp over Treasuries → details ▾
If the stock fell to about $4.63 (down 99%), Bio-Rad Laboratories, Inc. would be worth roughly what it owes.
Total debt $1.20B against a stock market value of $10.19B.
Distance to default 7.62 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $802.2M (short-term plus half of long-term), stock volatility 36.7%; Altman Z 3.86. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Hercules, CA 94547
US
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| DiVincenzo Jonathan | F-InKind | 951 | $369.95 | 2026-10-24 |
| DiVincenzo Jonathan | M-Exempt | 1,869 | — | 2026-10-24 |
| DiVincenzo Jonathan | M-Exempt | 1,869 | — | 2026-10-24 |
| EVRAN SEDAT | M-Exempt | 1,044 | — | 2026-10-20 |
| EVRAN SEDAT | F-InKind | 487 | $354.50 | 2026-10-20 |